DMAAR NASDAQ
Drugs Made In America Acquisition Corp. Rights
1W: +2.3%
1M: +56.0%
3M: +0.0%
YTD: -29.8%
1Y: -3.9%
$0.12
+0.00 (+0.24%)
Weekly Expected Move ±29.2%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$2.5M
52W Range0.1171-0.1271
Volume184,701
Avg Volume85,148
Beta4.31
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORoger Bendelac
SectorFinancial Services
IndustryShell Companies
IPO Date2026-01-13
Websitedmaacorp.com
1 East Broward Blvd Suite 700
Fort Lauderdale, FL 33301
US
Fort Lauderdale, FL 33301
US
+1 212 906 1222
About Drugs Made In America Acquisition Corp. Rights
Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Drugs Made In Americ | P-Purchase | 30,000 | — | 2025-02-18 |
| Drugs Made In Americ | P-Purchase | 30,000 | — | 2025-02-18 |
| Stockwell Lynn | P-Purchase | 30,000 | — | 2025-02-18 |
| Stockwell Lynn | P-Purchase | 30,000 | — | 2025-02-18 |
| Drugs Made In Americ | P-Purchase | 400,000 | — | 2025-01-29 |